Sartorius and Repligen Introduce Next-Generation Bioreactors
Sarorius Stedim Biotech (SSB) (Euronext: DIM), an international supplier for the biopharmaceutical industry, and Repligen Corporation (NASDAQ:RGEN), a global life sciences company focused on bioprocessing technologies, have entered into a collaboration agreement to integrate Repligen’s XCell ATF cell retention control technology into SSB’s BIOSTAT STR large-scale single-use bioreactors to create novel perfusion-enabled bioreactors.
As a result of this collaboration, end users will stand to benefit from a single control system for 50 L to 2,000 L bioreactors used in perfusion cell culture applications. This single interface is designed to control cell growth, fluid management and cell retention in continuous and intensified bioprocessing and, ultimately, simplify the development and cGMP manufacture of biological drugs. Through the partnership, Sartorius Stedim Biotech and Repligen will further collaborate to equip SSB’s recently launched ambr 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo hollow fiber filter technology. The bioreactor system will be sold by SSB as a complete single-use assembly. This optimal design conserves hollow fiber filter technology across scales, enabling customers to fast track development and scale up their cell culture perfusion processes.